[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100178275":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":10,"locations":31,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":10,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"National Cancer Institute (NCI)","NIH",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ancillary-Correlative (laboratory biomarkre analysis)",null,"Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.",[13,14],"Other: medical chart review","Other: laboratory biomarker analysis",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"OTHER","medical chart review","Correlative studies",[9],[22],"chart review",{"type":17,"name":24,"description":19,"armGroupLabels":25,"otherNames":10},"laboratory biomarker analysis",[9],[27],{"name":28,"affiliation":29,"role":30},"Lesley Seymour","Canadian Cancer Trials Group","PRINCIPAL_INVESTIGATOR",[32],{"facility":33,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"National Cancer Institute of Canada Clinical Trials Group","Kingston","Ontario","K7L 3N6","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-76.48098,44.22976,{"lat":43,"lon":42},[46,51],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"Lesley K. Seymour","CONTACT","613-533-6430","lseymour@ctg.queensu.ca",{"name":47,"role":30,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100178275","biomarkers-in-predicting-treatment-response-in-samples-from-patients-with-early-stage-non-small-cell-lung-cancer-previously-treated-with-adjuvant-chemotherapy-100178275",false,"NCT01595074","Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy","The Identification, Validation and Implemention of Prognostic and\u002For Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Samples from patients treated in 4 adjuvant chemotherapy (ACT) for early-stage non-small cell lung cancer (NSCLC) pivotal trials:\n\n  * International Adjuvant Lung Cancer Trail (IALT)\n  * Cancer and Leukemia Group B (CALGB)-9633\n  * CAN-NCIC-BR10\n  * Adjuvant Navelbine International Trialist Association (ANITA)\n* Not specified\n* See Disease Characteristics","ALL","18 Years",{"count":64,"type":65},950,"ESTIMATED","OBSERVATIONAL","This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.",[69,70,71,72,73],"Stage IA Non-small Cell Lung Cancer","Stage IB Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2013-09-19",{"date":77,"type":65},"2013-09-20",{"date":79,"type":10},"2012-05",{"name":5,"class":6},1]